Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …

Chimeric antigen receptor (CAR)-modified T cell therapy is a rapidly emerging
immunotherapeutic approach that is revolutionizing cancer treatment. The impressive …

In recent years, we have seen rapid expansion of chimeric antigen receptor T‐cell (CAR‐T)
therapies in multiple malignancies. CAR‐T therapy has profoundly altered the treatment …

The development of chimeric antigen receptor (CAR) T‐cell therapy for select hematological
malignancies represents one of the most remarkable therapeutic advances in the past …

Simple Summary In relapsed, refractory B cell malignancies and multiple myeloma, chimeric
antigen receptor (CAR) T cell therapy has represented a major scientific advancement with …

Background Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven
efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M …

Chimeric antigen receptor (CAR)-engineered T cells represent a breakthrough in
personalized medicine. In this strategy, a patient's own T lymphocytes are genetically …

The therapeutic landscape of multiple myeloma (MM) has benefited from an emergence of
novel therapies over the last decade. By inducing T-cell kill of target cancer cells, chimeric …

Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy
that has revolutionized the treatment of certain hematological malignancies, including B-cell …

Introduction: Chimeric antigen receptor (CAR) T cell therapies have demonstrated robust
and sustained clinical responses in several hematologic malignancies. Data suggest that …